PositiveID Market Opportunity
IMO it's going to be 2017 before we see the full 90 million to 120 million dollar revenue from the "Razor Blade" Reagent sales. So I for one intend to stay long on the stock and expect to start selling stock in late 2016. Maybe we will see a surge in activity after the first contract is awarded but if you intend to see the projected pps of $ 6.00 you might want to look to other investments or revenue for immediately planned purchases.
???One question that really needs to be answered and announced is when will Boeing begin tooling up for production of the M-Band Units??? I'm sure they could be sold if they were available.
I am basing this opinion on the slide deck presented at the PositiveID Investors Presentation 2013.
From PositiveID 2013 Investors Presentation
PositiveID Market Opportunity
BioWatch Gen-3 procurement anticipates 2,500 units to be deployed over 2013-2017; the 2,500 units will require monthly reagent/assay replacement (the “razor blade”)
2,500 units will provide recurring revenue base of between $90-120M revenue annually at 15-20% margins
The U.S. market non-BioWatch (bases and embassies) should be of like size to BioWatch
Europe/Asia/Middle East markets could be significantly larger than U.S. market
Deal Terms
A License Agreement and a Teaming Agreement with The Boeing Company
Boeing becomes the exclusive manufacturer and distributor of M-BAND units (in North America – except
SAIC contract with DTRA) – Exclusive for the $3.1B BioWatch Gen-3 contract, expected beginning in 2013
PositiveID is exclusive provider of monthly reagents/assays to Boeing for any M-BAND units built and sold
Boeing pays PositiveID $2.5 million license fee in December 2012-April 2013
Other opportunities
PositiveID has submitted or in-process bids for other
opportunities including with HHS, DHS, DTRA (Army) and NASA
Long Term Positive
Currently: HOLDING
Market Data 
Markets 
AI
